Bank of New York Mellon Corp Has $2.10 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Bank of New York Mellon Corp boosted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 860.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 80,935 shares of the company’s stock after purchasing an additional 72,509 shares during the quarter. Bank of New York Mellon Corp owned about 0.28% of Dianthus Therapeutics worth $2,095,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of DNTH. Bain Capital Life Sciences Investors LLC purchased a new position in Dianthus Therapeutics during the 1st quarter worth $89,761,000. RA Capital Management L.P. purchased a new position in Dianthus Therapeutics during the 1st quarter worth $69,990,000. Octagon Capital Advisors LP boosted its holdings in Dianthus Therapeutics by 15.4% during the 4th quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after acquiring an additional 74,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after acquiring an additional 384,182 shares during the last quarter. Finally, Janus Henderson Group PLC purchased a new position in Dianthus Therapeutics during the 1st quarter worth $11,251,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $25.99 on Wednesday. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77. The stock has a market capitalization of $762.81 million, a PE ratio of -4.46 and a beta of 1.85. The business’s fifty day moving average is $28.12 and its 200 day moving average is $26.11.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The firm had revenue of $1.86 million during the quarter, compared to the consensus estimate of $0.63 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DNTH. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They set an “overweight” rating on the stock. Robert W. Baird assumed coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock. Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Wedbush lowered their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Finally, Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $44.71.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.